1. Home
  2. GNFT

GNFT

GENFIT S.A.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Founded: 1999 Country:
France
France
Employees: N/A City: N/A
Market Cap: 175.5M IPO Year: 2019
Target Price: $11.00 AVG Volume (30 days): 11.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.62 EPS Growth: N/A
52 Week Low/High: $2.89 - $4.75 Next Earning Date: 04-04-2024
Revenue: $42,417,778 Revenue Growth: -55.39%
Revenue Growth (this year): 157.45% Revenue Growth (next year): -45.10%

Share on Social Networks: